Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RPRX |
---|---|---|
09:32 ET | 21272 | 28.355 |
09:34 ET | 3166 | 28.36 |
09:36 ET | 5579 | 28.29 |
09:38 ET | 2050 | 28.27 |
09:39 ET | 5291 | 28.25 |
09:41 ET | 3333 | 28.26 |
09:43 ET | 3292 | 28.3 |
09:45 ET | 7326 | 28.31 |
09:48 ET | 6052 | 28.3 |
09:50 ET | 3083 | 28.285 |
09:52 ET | 2673 | 28.285 |
09:54 ET | 7377 | 28.275 |
09:56 ET | 8466 | 28.28 |
09:57 ET | 2372 | 28.29 |
09:59 ET | 5191 | 28.35 |
10:01 ET | 5372 | 28.37 |
10:03 ET | 4454 | 28.295 |
10:06 ET | 9396 | 28.3 |
10:08 ET | 4028 | 28.325 |
10:10 ET | 4539 | 28.295 |
10:12 ET | 9772 | 28.325 |
10:14 ET | 5257 | 28.33 |
10:15 ET | 3034 | 28.345 |
10:17 ET | 10755 | 28.35 |
10:19 ET | 5230 | 28.335 |
10:21 ET | 4409 | 28.35 |
10:24 ET | 1943 | 28.36 |
10:26 ET | 2939 | 28.39 |
10:28 ET | 5513 | 28.41 |
10:30 ET | 5731 | 28.39 |
10:32 ET | 3763 | 28.38 |
10:33 ET | 11564 | 28.31 |
10:35 ET | 3757 | 28.345 |
10:37 ET | 2111 | 28.36 |
10:39 ET | 5291 | 28.375 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Royalty Pharma PLC | 16.7B | 18.9x | +1.83% |
Amneal Pharmaceuticals Inc | 2.6B | -13.4x | --- |
Endo Inc | 1.9B | 0.4x | --- |
Catalent Inc | 10.9B | -10.5x | --- |
Jazz Pharmaceuticals PLC | 6.8B | 19.3x | -3.53% |
Mallinckrodt PLC | 1.6M | 0.0x | --- |
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.7B |
---|---|
Revenue (TTM) | $2.2B |
Shares Outstanding | 593.5M |
Dividend Yield | 2.96% |
Annual Dividend Rate | 0.8400 USD |
Ex-Dividend Date | 08-16-24 |
Pay Date | 09-13-24 |
Beta | 0.46 |
EPS | $1.50 |
Book Value | $14.61 |
P/E Ratio | 18.9x |
Price/Sales (TTM) | 7.5 |
Price/Cash Flow (TTM) | 19.9x |
Operating Margin | 42.91% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.